GMI-1359

DRUG2 trials

Sponsors

GlycoMimetics Incorporated

Conditions

Breast CancerBreast Cancer MetastaticHR+ Metastatic Breast CancerHealthy

Phase 1

Placebo-Controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of GMI-1359 in Healthy Volunteers

CompletedNCT02931214

GlycoMimetics IncorporatedHealthy

Start: 2016-08-31End: 2018-11-30Updated: 2019-03-04

A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer

TerminatedNCT04197999

GlycoMimetics IncorporatedBreast Cancer, Breast Cancer Metastatic, HR+ Metastatic Breast Cancer

Start: 2019-11-21End: 2021-08-25Updated: 2022-03-22

Related Papers

Co-Targeting E-Selectin/CXCR4 with GMI-1359 Facilitates AML Stem Cell Mobilization and Protects BM Niches from Anti-Leukemia Therapy

Blood2021-11-051 citations

Abstract CT144: Development of GMI-1359, a novel agent targeting tumor-microenvironment cross-talk in bone metastatic cancer

Cancer Research2021-07-012 citations